$95,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosed, from Q2 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to oncology, Medicare coverage, domestic production of essential drugs, supply chain security, PILLS Act, Biosecure Act and efforts to onshore manufacturing, Loans and grants for biologic production in America
Issues related to drug development, oncology, IRA implementation, supply chain security, BIOSECURE as a policy matter, PILLS Act, and domestic production of essential drugs. Strategic National Stockpile of acute radiation syndrome medical counter measures. Administration for Strategic Preparedness & Response."
You can find more data on corporate lobbying on Quiver Quantitative.
CHRS Hedge Fund Activity
We have seen 77 institutional investors add shares of CHRS stock to their portfolio, and 44 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ALYESKA INVESTMENT GROUP, L.P. added 2,250,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $3,802,500
- TWO SIGMA INVESTMENTS, LP added 1,798,126 shares (+356.9%) to their portfolio in Q1 2026, for an estimated $3,038,832
- PROPEL BIO MANAGEMENT, LLC added 1,420,550 shares (+inf%) to their portfolio in Q1 2026, for an estimated $2,400,729
- HUDSON BAY CAPITAL MANAGEMENT LP added 869,980 shares (+104.2%) to their portfolio in Q1 2026, for an estimated $1,470,266
- JANE STREET GROUP, LLC removed 563,016 shares (-93.3%) from their portfolio in Q1 2026, for an estimated $951,497
- GOLDMAN SACHS GROUP INC added 389,021 shares (+126.7%) to their portfolio in Q1 2026, for an estimated $657,445
- SEI INVESTMENTS CO added 377,134 shares (+492.2%) to their portfolio in Q1 2026, for an estimated $637,356
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
Read full article here »
View the Zacks #1 Rank List
Lobbying Update: $95,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosed
$95,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosed, from Q2 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to oncology, Medicare coverage, domestic production of essential drugs, supply chain security, PILLS Act, Biosecure Act and efforts to onshore manufacturing, Loans and grants for biologic production in America Issues related to drug development, oncology, IRA implementation, supply chain security, BIOSECURE as a policy matter, PILLS Act, and domestic production of essential drugs. Strategic National Stockpile of acute radiation syndrome medical counter measures. Administration for Strategic Preparedness & Response."
You can find more data on corporate lobbying on Quiver Quantitative.
CHRS Hedge Fund Activity
We have seen 77 institutional investors add shares of CHRS stock to their portfolio, and 44 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
Read full article here »